We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Benzene ring

15 July 2015 By Robert Cyran

The cancer drug giant is scooping up Receptos for 16 times its 2013 float price. The target has promise but no approved drug, yet Celgene’s market value rose by nearly $5.5 bln. With the bio bull market rewarding both seller and buyer, dealmaking is getting pumped up on steroids.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)